<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05798754</url>
  </required_header>
  <id_info>
    <org_study_id>21/03/2023/ID</org_study_id>
    <nct_id>NCT05798754</nct_id>
  </id_info>
  <brief_title>Efficacy of CompuFlo® Technology in Thoracic Epidural Space Identification</brief_title>
  <official_title>Correlation of Standard Loss of Resistance Technique Versus the CompuFlo®-Assisted Technology for Thoracic Epidural Space Identification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General and Maternity Hospital of Athens Elena Venizelou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General and Maternity Hospital of Athens Elena Venizelou</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this non inferiority trial is to assess the efficacy of CompuFlo® technology to&#xD;
      identify the thoracic epidural space in relation to the gold standard loss of resistance&#xD;
      technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non inferiority trial shouts to adress whether the CompuFlo® technology to identify the&#xD;
      thoracic epidural space is less efficacious to the gold standard loss of resistance technique&#xD;
      (LOR). After informed signed consent patients that will be subjected to gynecological&#xD;
      operations and meet the inclusion criteria will be eligible to participate. All operations&#xD;
      will be performed under general anesthesia and thoracic epidural analgesia regardless of&#xD;
      study arm. Patients will be randomly allocated into two study groups. In the first study&#xD;
      group (Group LOR) the thoracic epidural space will be identified by the LOR technique and in&#xD;
      the second study group (Group C) by the CompuFlo® technology. The primary outcome is the&#xD;
      percentage of thoracic epidural space identification success in either study group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective blind, non-inferiority randomized trial</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Member of the study group that assesses the epidural's success</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of successful thoracic epidural space identification</measure>
    <time_frame>Loss of sensation to cold 20 min after the first dose administered through the epidural catheter</time_frame>
    <description>The success of the thoracic epidural space identification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of successful thoracic epidural space identification by the first attempt</measure>
    <time_frame>Loss of sensation to cold 20 min after the first dose administered through the epidural catheter during the first attempt</time_frame>
    <description>Percentage of successful thoracic epidural space identification by the first attempt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of attempts to successful thoracic epidural space identification</measure>
    <time_frame>Number of attempts to successful thoracic epidural space identification up to a maximum of 3 adressed as loss of sensation to cold 20 min after the first dose administered through the epidural catheter</time_frame>
    <description>Number of attempts to successful thoracic epidural space identification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to identify the thoracic epidural space</measure>
    <time_frame>Time to insertion of epidural needle (Tuohy) in the supraspinous ligament to insertion of the epidural catheter</time_frame>
    <description>Time to identify the thoracic epidural space</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From epidural needle insertion up to 72 hours postoperatively</time_frame>
    <description>Adverse events (dural puncture, epidural hematoma, neurological deficit)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Thoracic Epidural Space Identification</condition>
  <arm_group>
    <arm_group_label>Group LOR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The thoracic epidural space will be identified by the loss of resistance technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The thoracic epidural space will be identified by the CompuFlo® technology.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Loss of resistance (LOR) technique</intervention_name>
    <description>The thoracic epidural space will be identified by the loss of resistance (LOR) technique</description>
    <arm_group_label>Group LOR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CompuFlo® technology</intervention_name>
    <description>The thoracic epidural space will be identified by the CompuFlo® technology</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        American Society of Anesthesiologists (ASA) Physical Status Classification System I-III&#xD;
        Body mass index: 18 -35 kg/m2 Gynecological laparotomy with midline incision under general&#xD;
        anesthesia and thoracic epidural analgesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients' denial to participate in the study ASA Physical Status Classification System &gt;IV&#xD;
        Contraindications to epidural analgesia Patients with sepsis Patients with pre-existing&#xD;
        neurologic deficits Pre-existing operations in the thoracic spinal cord Emergency&#xD;
        operations Patients with end-stage cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantinos Stroumpoulis, PhD</last_name>
    <role>Study Director</role>
    <affiliation>General and Maternity Hopsital of Athens Helena Venizelou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georgia Micha, PhD</last_name>
    <email>mgeo3@yahoo.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ioannis Grypiotis, MSc</last_name>
    <phone>00302132051000</phone>
    <phone_ext>2214</phone_ext>
    <email>quality-secr@hospital-elena.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>&quot;Elena Venizelou&quot; General and Maternity Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>April 3, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thoracic</keyword>
  <keyword>epidural space</keyword>
  <keyword>loss of resistance technique</keyword>
  <keyword>CompuFlo® technology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm, Dissecting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

